Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) EBITDA (2019 - 2025)

Historic EBITDA for Harmony Biosciences Holdings (HRMY) over the last 7 years, with Q3 2025 value amounting to $51.0 million.

  • Harmony Biosciences Holdings' EBITDA rose 887.75% to $51.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $185.5 million, marking a year-over-year increase of 5005.99%. This contributed to the annual value of $145.6 million for FY2024, which is 1282.96% up from last year.
  • Harmony Biosciences Holdings' EBITDA amounted to $51.0 million in Q3 2025, which was up 887.75% from $39.8 million recorded in Q2 2025.
  • Harmony Biosciences Holdings' 5-year EBITDA high stood at $87.8 million for Q3 2022, and its period low was -$9.6 million during Q3 2021.
  • Its 5-year average for EBITDA is $33.4 million, with a median of $33.8 million in 2023.
  • In the last 5 years, Harmony Biosciences Holdings' EBITDA plummeted by 19267.82% in 2021 and then skyrocketed by 101261.95% in 2022.
  • Over the past 5 years, Harmony Biosciences Holdings' EBITDA (Quarter) stood at $22.7 million in 2021, then skyrocketed by 113.68% to $48.5 million in 2022, then plummeted by 44.11% to $27.1 million in 2023, then surged by 80.8% to $49.0 million in 2024, then grew by 3.96% to $51.0 million in 2025.
  • Its last three reported values are $51.0 million in Q3 2025, $39.8 million for Q2 2025, and $45.7 million during Q1 2025.